RT Journal Article
SR Electronic
T1 Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP bjophthalmol-2017-311805
DO 10.1136/bjophthalmol-2017-311805
A1 Catharina Busch
A1 Matus Rehak
A1 Chintan Sarvariya
A1 Dinah Zur
A1 Matias Iglicki
A1 Luiz H Lima
A1 Alessandro Invernizzi
A1 Francesco Viola
A1 Kushal Agrawal
A1 Suthasinee Sinawat
A1 Aude Couturier
A1 Aanchal Mehta
A1 Rakesh Juneja
A1 Hardik Jain
A1 Aniruddha Kishandutt Agarwal
A1 Neha Goel
A1 Manish Nagpal
A1 Vishali Gupta
A1 Alay Banker
A1 Anat Loewenstein
A1 Mali Okada
A1 Ali Osman Saatci
A1 Ahmad M Mansour
A1 Jay Chhablani
YR 2018
UL http://bjo.bmj.com/content/early/2018/06/11/bjophthalmol-2017-311805.abstract
AB Background To evaluate the functional long-term outcome in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) treated with dexamethasone implant (DEX implant) and to identify its clinical predictors.Methods A 24-month, retrospective, multinational, real-world study. Chart review of patients with either naïve or recurrent MO secondary to CRVO/BRVO treated with DEX implant, including best-corrected visual acuity (BCVA), central subfield thickness (CST), demographic baseline characteristics and details of any additional treatment during follow-up.Results A total of 155 eyes (65 CRVO, 90 BRVO) from 155 patients were included. At 24 months, mean BCVA did not change significantly in CRVO (−2.1±24.5 letters, p=0.96) and BRVO patients (1.3±27.0 letters, p=0.07). A worse baseline BCVA (p<0.001), visual acuity (VA) gain ≥5 letters at 2 months (p=0.006) and no need for adjunctive intravitreal therapy after first DEX implant (p=0.001) were associated with a better final BCVA gain. Treatment-naïve patients (p=0.006, OR: 0.25, 95% CI 0.11 to 0.57) and those with a baseline CST≤400 µm (p=0.02, OR: 0.25, 95% CI 0.10 to 0.63) were identified as being less likely to need additional intravitreal therapy.Conclusion Clinical baseline characteristics and the early treatment response were identified as possible predictors for long-term outcome and the need of adjunctive intravitreal therapy in MO secondary to BRVO/CRVO treated by DEX implant.